FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Shares of Regeneron are down more than 10% today after the company announced on Friday evening, after market close, that the Phase 3 study of fianlimab did not achieve a statistically significant primary endpoint in progression-free survival (PFS). The advanced clinical trials were assessing fianlimab in combination with cemiplimab (PD-1 inhibitor) for first-line unresectable or metastatic melanoma, a skin cancer that has spread beyond its original location versus pembrolizumab (PD-1 inhibitor), which is Merck's blockbuster oncology drug, Keytruda. While the company aims to present detailed data at an upcoming medical meeting, the release reflects diminished prospects for what had been anticipated as a highly promising treatment with a blockbuster potential, in our view. We lower our target price to $650 from $846, based on 12.4x our 2027 EPS estimate, a discount to REGN's 10-year historical forward P/E average. We retain our 2026 EPS estimate at $45.59 and our 2027 EPS estimate at $52.62.

Related Articles

Research

Research Alert: CFRA Maintains Sell Opinion On Shares Of Versant Media Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price at $35, applying an EV/EBITDA multiple of 3.4x to our 2026 estimate, a slight discount to peers. We lower our 2026 EPS estimate by $0.34 to $5.46 and trim 2027's by $0.34 to $7.67. VSNT experienced ongoing pressure on its Pay TV business, particularly affecting both linear distribution and advertising revenues. This was largely attributed to continued cord-cutting trends, which led to a 7% Y/Y decline in linear distribution revenue and a 5% Y/Y decrease in advertising revenue, although the advertising decline showed improvement compared to the prior year's drop. These trends were described as consistent with the prior trajectory and were partially mitigated by other growth areas but remain a headwind for the company's traditional TV business model.

$VSNT
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Quebecor, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by CAD10 to CAD70, applying an EV/EBITDA multiple of 8.4x to our 2026 estimate, comparable to its 3-year historical average multiple at 8.1x. We increase our 2026 EPS estimate by CAD0.11 to CAD4.29 and raise 2027's by CAD0.13 to CAD4.67. The media segment continues to face a deep structural crisis, characterized by challenges such as the dominance of large players in the advertising market, declining television subscriptions, reduced support from the Canadian media fund, unfair competition from public broadcasters, and a heavy regulatory burden from the CRTC. These factors undermine private broadcasters and threaten the viability of local content production and distribution. The wireless market experienced an aggressively promotional environment, leading to unsustainable pricing and heightened competition. This environment resulted in lower organic growth and net mobile additions, as the major players primarily competed for each other's customers at reduced prices.

$QBR.B
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of The Cooper Companies

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $21 to $63, 13.6x our FY 26 EPS estimate (up $0.02 to $4.62; FY 27 estimate up $0.01 to $5.02). Our target multiple reflects a discount to COO's one-year historical forward average of 17.2x and well below the company's 24.9x forward average over the past five years amid ongoing restructuring efforts and uncertainty about long-term strategy given the ongoing strategic business review. We also note recent tariff headwinds and market disruption from the ongoing U.S./Iran conflict. Nonetheless, we expect near-term sales and margin improvement, with recent U.S. vision business trends appearing supportive and restructuring efforts likely to improve profitability, in our view. We anticipate near 5.6% sales growth in FY 26, above the 5.1% growth seen in FY 25, while we see adjusted operating margin improvement to near 26.7% in FY 26 from 25.8%.

$COO